Mezzion Pharma Co., Ltd. today announced written feedback from the U.S. Food and Drug Administration (FDA) following a pre-IND Type C Guidance meeting interaction for the development of udenafil in ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 3—(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic ...

A large study of patients in the US Veterans Administration health system revealed that patients with ADPKD had a much higher rates of chronic obstructive pulmonary disease, hypertension, diabetes, ...

Data from this Australian study showed a higher prevalence of intracranial aneurysms (ICAs) in patients with ADPKD compared with the general population. Many patients in the study had no known risk ...

U.S.-based researchers examined the burden of imaging in a population of patients with ADPKD, versus that of patients with chronic kidney disease (CKD). People with ADPKD underwent more abdominal ...

Clinicians should monitor patients with stones, even if they are asymptomatic, to slow kidney function decline, investigators suggest. Even asymptomatic kidney stones may spur kidney function decline ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program. Topline results ...

Developing new gene therapies for autosomal dominant polycystic kidney disease (ADPKD) is still a challenge to date. A group of researchers from the Johns Hopkins Medicine in Baltimore has presented ...